Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Hyperfine, Inc. - Class A Common Stock (NQ: HYPR )

0.8100 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 54
Open 0.8100
Bid (Size) 0.8621 (1)
Ask (Size) 1.040 (12)
Prev. Close 0.8100
Today's Range 0.8100 - 0.8100
52wk Range 0.7951 - 3.280
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Leading Institutions Enroll First Alzheimer’s Patients Receiving Amyloid-Targeting Therapy in CARE PMR Study
From Hyperfine, Inc.
Via Business Wire
HYPR Stock Earnings: Hyperfine Beats EPS, Misses Revenue for Q4 2023
HYPR stock results show that Hyperfine beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2023. 
Via InvestorPlace

Performance

YTD
-28.32%
-28.32%
1 Month
-31.36%
-31.36%
3 Month
-15.62%
-15.62%
6 Month
-56.45%
-56.45%
1 Year
-43.75%
-43.75%

More News

Read More
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Recap: Hyperfine Q4 Earnings
Via Benzinga
Hyperfine Earnings Preview
Via Benzinga
Recap: Hyperfine Q3 Earnings
Via Benzinga
Hyperfine, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results
From Hyperfine, Inc.
Via GlobeNewswire
Earnings Scheduled For March 21, 2024
Via Benzinga
Hyperfine, Inc. Collaborates with King’s College London to Demonstrate the Swoop® System and UNITY Project to The Princess Royal
From Hyperfine, Inc.
Via Business Wire
Hyperfine, Inc. to Announce Fourth Quarter and Full Year 2023 Financial Results on March 21, 2024
From Hyperfine, Inc.
Via Business Wire
Hyperfine, Inc. to Present at the Oppenheimer 34th Annual Healthcare Conference
From Hyperfine, Inc.
Via Business Wire
Hyperfine, Inc. Announces Collaboration with Athletic Heart to Provide Vital Brain Health Imaging for Former Professional Athletes
From Hyperfine, Inc.
Via Business Wire
Hyperfine, Inc. Celebrates Breadth of Swoop® System Data Presented at the 2024 International Stroke Conference and Provides an Update on Enrollment in ACTION PMR Stroke Observational Study
From Hyperfine, Inc.
Via Business Wire
Why VCI Global Shares Are Trading Lower By Around 30%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Via InvestorPlace
Hyperfine, Inc. Launches AI-powered Brain Imaging Software for Enhanced Image Quality and Ease of Use
From Hyperfine, Inc.
Via Business Wire
Hyperfine, Inc. Announces Presentations on Clinical Advancements at RSNA 2023
From Hyperfine, Inc.
Via Business Wire
Hyperfine, Inc. to Present at the Piper Sandler 35th Annual Healthcare Conference
From Hyperfine, Inc.
Via Business Wire
Hyperfine, Inc. Reports Third Quarter 2023 Financial Results
From Hyperfine, Inc.
Via GlobeNewswire
Observational Study Finds That Hyperfine, Inc. Portable MR Brain Imaging System Assists Clinicians in Early Detection of Acute Brain Injury in ECMO Patients
From Hyperfine, Inc.
Via Business Wire
Hyperfine, Inc. to Announce Third Quarter Financial Results on November 9, 2023
From Hyperfine, Inc.
Via Business Wire
Hyperfine, Inc. Announces Promotions of Two Key Clinical Affairs Executives
From Hyperfine, Inc.
Via Business Wire
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Hyperfine, Inc. Receives FDA Clearance for Updated AI-powered Software with Improved Image Quality for All Swoop® System Sequences
From Hyperfine, Inc.
Via Business Wire
Hyperfine, Inc. to Present at Gilmartin Group Emerging Growth Showcase
From Hyperfine, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.